Matches in UGent Biblio for { <https://biblio.ugent.be/publication/2014504#aggregation> ?p ?o. }
Showing items 1 to 36 of
36
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B218561.
- aggregation creator B218562.
- aggregation creator B218563.
- aggregation creator B218564.
- aggregation creator person.
- aggregation date "2011".
- aggregation format "application/pdf".
- aggregation hasFormat 2014504.bibtex.
- aggregation hasFormat 2014504.csv.
- aggregation hasFormat 2014504.dc.
- aggregation hasFormat 2014504.didl.
- aggregation hasFormat 2014504.doc.
- aggregation hasFormat 2014504.json.
- aggregation hasFormat 2014504.mets.
- aggregation hasFormat 2014504.mods.
- aggregation hasFormat 2014504.rdf.
- aggregation hasFormat 2014504.ris.
- aggregation hasFormat 2014504.txt.
- aggregation hasFormat 2014504.xls.
- aggregation hasFormat 2014504.yaml.
- aggregation isPartOf urn:issn:1076-0296.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL".
- aggregation abstract "The efficacy and safety of low-molecular-weight heparins (LMWHs) versus unfractionated heparin (UFH) has been demonstrated for the prevention of venous thromboembolism (VTE) after acute ischemic stroke. Few data exist regarding the economic impact of LMWHs versus UFH in this population. A decision-analytic model was constructed using clinical information from the Prevention of VTE after Acute Ischemic stroke with LMWH Enoxaparin (PREVAIL) study, and drug costs and mean Centers for Medicare & Medicaid Services event costs. When considering the total cost of events and drugs, enoxaparin was associated with cost-savings of $895 per patient compared with UFH ($2018 vs $2913). Findings were retained within the univariate and multivariate analyses. From a payer perspective, enoxaparin was cost-effective compared with UFH in patients with acute ischemic stroke. The difference was driven by the lower clinical event rates with enoxaparin. Use of enoxaparin may help to reduce the clinical and economic burden of VTE.".
- aggregation authorList BK482274.
- aggregation endPage "157".
- aggregation issue "2".
- aggregation startPage "150".
- aggregation volume "17".
- aggregation aggregates 2039908.
- aggregation isDescribedBy 2014504.
- aggregation similarTo 1076029610389026.
- aggregation similarTo LU-2014504.